Abstract
Phenacetin O-deethylation (POD) exhibits biphasic kinetics in human liver microsomes. Although cytochrome P-450 (CYP) 1A2 is responsible for the high-affinity component of POD, the enzyme(s) that catalyzes the low-affinity reaction is still unknown. We examined the roles of human CYPs in POD by using human liver microsomes and recombinant CYPs from baculovirus-infected insect cells. Of the recombinant CYPs studied, CYP1A2 showed the highest POD activity. CYP1A1, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 also showed POD activity at 500 μM phenacetin. KM values of recombinant CYP1A2 and CYP2E1 (28 ± 2 μM and 785 ± 125 μM, respectively) were similar to those of the high- and low-affinity components of POD in pooled human liver microsomes (15 ± 5 and 894 ± 189 μM, respectively). Fluvoxamine (10 μM) and anti-CYP1A2 antibodies potently inhibited POD activity at 500 μM phenacetin in pooled human liver microsomes to 22.8 and 34.2% of controls, respectively. CYP2E1 inhibitors diethyldithiocarbamate and aniline also reduced POD activity. The combination of fluvoxamine (10 μM) and aniline (1 mM) further inhibited the residual POD activity not inhibited by fluvoxamine alone. Microsomal POD activity in 12 human livers in the absence of fluvoxamine was correlated with immunoquantified CYP1A2 levels (r = 0.961,p < .001) and, in the presence of 10 μM fluvoxamine, was correlated with immunoquantified CYP2E1 levels (r = 0.589, p < .01) or chlorzoxazone 6-hydroxylase activity (r = 0.823,p < .001). These results suggest that CYP2E1 is responsible for the low-affinity component of POD in human liver microsomes.
Footnotes
-
Send reprint requests to: Kaoru Kobayashi, Ph.D., Laboratory of Biochemical Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Chiba University, Yayoi-cho 1-33, Inage-ku, Chiba 263-8522, Japan. E-mail: kaoruk{at}p.chiba-u.ac.jp
- Abbreviations used are::
- CYP
- cytochrome P-450
- POD
- phenacetin O-deethylation
- TAO
- troleandomycin
- DDC
- N,N- diethyldithiocarbamate
- Received February 8, 1999.
- Accepted May 3, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|